NCT01068782Phase 2Terminated

Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

Study sponsor: Exelixis

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2011-05Actual
Enrollment · participants19Actual
Source updated2026-02-25Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: In the Randomized Phase, to evaluate the preliminary efficacy and tolerability of multiple regimens of XL184 Measure: In the Expansion Phase, to evaluate the efficacy of XL184 treatment. After: Measure: Randomized Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Measure: Expansion Phase: Objective Response Rate (ORR).

Recruitment status changed

Before: Completed. After: Terminated.

Check registry source